Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lucid Psycheceuticals
Toronto, Ontario, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Lucid Psycheceuticals, now a subsidiary of FSD Pharma, is advancing two lead programs—LUCID-PSYCH (for depression/mental health) and LUCID-MS (for multiple sclerosis), both at preclinical/IND-enabling stage. LUCID-MS has shown excellent efficacy in animal models without immunosuppression and is IND-ready; LUCID-PSYCH, identified using AI, is advancing toward Phase 1 for depression[4][5][6].
- Therapeutic areas
- ImmunologyNeurologyPsychiatry
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Partnerships
University Health Network (UHN)—exclusive IP licensingCovar Pharmaceuticals (CDMO/contract manufacturing)
Beyond the preview
Go deeper on Lucid Psycheceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lucid Psycheceuticals.